Loading stock…

IDEAYA Biosciences, Inc. (IDYA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

IDEAYA Biosciences, Inc.

IDYAMarket cap $3.50BPrice $36.3

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

IDEAYA Biosciences develops targeted cancer therapies using synthetic lethality — exploiting genetic weaknesses to kill tumor cells while sparing healthy ones. Its lead program partners with GSK, betting precision science can outsmart cancer where chemotherapy fails.

In Bastion Portfolios?

52W Return+24%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+63%10

Revenue Forecast

Rev CAGR (1y)-84%1

Rev CAGR (3y)+2%2

Rev CAGR (5y)+40%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-93%1

Net Income Margin-75%1

Free Cash Flow Margin-49%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-16%1

ROA-15%1

Earnings Stabilityna–

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.95

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.3%2

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return-4%5

YTD return+5%6

Mid term

Price vs 52wHigh85%7

1 year return+35%8

Long term

3 year return+36%5

5 year return+42%5

Risk Shield

Price Risk

Beta1.32

Volatility45%4

Free Cash Flow

Free Cash Flow Margin-49%1

Free Cash Flow Yield-3.3%2

Quality

ROCE-20%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

IDYAIDEAYA Biosciences

Revenue FY25$219M

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+63%10

Revenue, next 1Y-84%1

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+40%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 63%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 40%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 63%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-4%5

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+35%8

3-year return+36%5

5-year return+42%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

WATCH

Average long-term results. Multi-year returns are middling (+36% over three years and +42% over five), roughly average for the market.

Returns sit at the market level over the past month (-7%), over three months (-4%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on IDEAYA Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IDYAIDEAYA Biosciences

Revenue FY25$219M

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+63%10

Revenue, next 1Y-84%1

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+40%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 63%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 40%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 63%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-4%5

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+35%8

3-year return+36%5

5-year return+42%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

WATCH

Average long-term results. Multi-year returns are middling (+36% over three years and +42% over five), roughly average for the market.

Returns sit at the market level over the past month (-7%), over three months (-4%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on IDEAYA Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community